On November 1, 2023, VYNE Therapeutics Inc. closed the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.96 USD | 0.00% |
|
+8.29% | -15.88% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.88% | 28.48M | |
+59.97% | 827B | |
+38.38% | 634B | |
-6.18% | 350B | |
+15.61% | 319B | |
+8.44% | 294B | |
+12.68% | 240B | |
+14.40% | 221B | |
+0.04% | 219B | |
+9.68% | 167B |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors